AlphaCentric Advisors’s Fusion Pharmaceuticals Inc. Common Shares FUSN Stock Holding History

AlphaCentric Advisors’s Portfolio FUSN Stock Details FUSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$417K	Buy	100,000 +28,500	+40%	+$178K	0.12%	68
2021 Q3	$566K	Hold	71,500	–	–	0.14%	61
2021 Q2	$578K	Buy	71,500 +34,500	+93%	+$297K	0.16%	54
2021 Q1	$397K	Buy	37,000 +20,500	+124%	+$240K	0.13%	57
2020 Q4	$194K	Buy	16,500 +12,700	+334%	+$160K	0.08%	71
2020 Q3	$46K	Buy	3,800 +2,000	+111%	+$27.3K	0.02%	113
2020 Q2	$31K	Buy	+1,800	New	+$31.4K	0.02%	105

Other funds holding FUSN

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

PBPIA

Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

AlphaCentric Advisors's FUSN Position: Q4 2021 in Review

AlphaCentric Advisors increased its Fusion Pharmaceuticals Inc. Common Shares (FUSN) stake by 40% in Q4 2021, buying an estimated $178K and bringing the position to 100,000 shares worth $417K. The position accounts for 0.12% of the portfolio, ranked #68.

AlphaCentric Advisors first reported a position in FUSN in Q2 2020 and has held it in 7 quarters since. The position peaked at $578K in Q2 2021. 32 funds tracked by Wall St. Rank hold FUSN as of Q4 2021.

AlphaCentric Advisors held 100,000 shares of Fusion Pharmaceuticals Inc. Common Shares worth $417K as of Q4 2021.
AlphaCentric Advisors bought 28,500 Fusion Pharmaceuticals Inc. Common Shares shares in Q4 2021, an estimated $178K.
Fusion Pharmaceuticals Inc. Common Shares made up 0.12% of AlphaCentric Advisors's portfolio in Q4 2021, its #68 holding.
AlphaCentric Advisors first reported a position in Fusion Pharmaceuticals Inc. Common Shares in Q2 2020 and has held it in 7 quarters since.
AlphaCentric Advisors's Fusion Pharmaceuticals Inc. Common Shares position peaked at $578K in Q2 2021.
32 funds tracked by Wall St. Rank held Fusion Pharmaceuticals Inc. Common Shares as of Q4 2021.

Based on AlphaCentric Advisors's 13F filing for Q4 2021, filed 25 Feb 2022.